



Emerald Health Therapeutics Appoints Paul R. Dillman, Jr. to Vice President of Sales and Marketing

Senior marketing executive with three decades global consumer packaged goods experience to lead Emerald's marketing and sales strategy

Victoria, BC, January 8, 2018 – Emerald Health Therapeutics Inc. (TSXV: EMH; OTCQX: EMHTF) ("Emerald") today announced the appointment of Paul R. Dillman, Jr., as the Company's Vice President of Sales and Marketing. Mr. Dillman will be responsible for marketing, sales, and customer service, and will lead Emerald's brand strategy and execution as the Company prepares for anticipated legalization of adult use cannabis in Canada by July 2018.

"Paul has been instrumental in preparing for and executing sales growth as a senior leader at some of the world's most successful fast-moving consumer packaged goods companies. His strategic and tactical marketing expertise will be invaluable as we position Emerald for leadership in the Canadian and global cannabis industry," said Chris Wagner, Chief Executive Officer of Emerald.

Mr. Dillman brings three decades of experience in global marketing, sales, and general management to Emerald and has held senior leadership positions at The Coca-Cola Company, AB InBev, Philip Morris, and Kraft Foods.

Mr. Dillman earned a Bachelor of Science from West Point (United States Military Academy) and a Master of Science in Systems Management from the University of Southern California.

"I'm thrilled to join the dynamic organization that Emerald is building," said Mr. Dillman. "With its current expansion projects and product innovation plans, Emerald is poised to be a premiere provider of cannabis for medical and adult-use consumers. I look forward to planning and executing a marketing and sales strategy that will contribute to this goal."

Mr. Dillman has been granted an option to acquire up to 150,000 common shares vesting over three years.

Join us on our journey of making lives better through cannabis science.

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) operates through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary and Licensed Producer under Canada's Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on

32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms, a partnership with Village Farms that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald's team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits by interacting with the human body's endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:

Robert Hill, CFO
(800) 757 3536 Ext. #722
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements."

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to expansion of Emerald's business; creation of strategic development opportunities; commercial operations; construction or conversion of production facilities; international opportunities for the Company; the Company becoming a leading Canadian supplier of cannabis products; expected timing of any of the above matters; and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, failure to obtain regulatory approval for closing of the proposed transaction or to meet the conditions set out in the Agreement; failure of the federal government to approve legislation legalizing sales of nontherapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; the Company's historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in the Company's annual information form and other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.